TAMOXIFEN CITRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H29NO.C6H8O7
Molecular Weight	563.6381
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CC\C(=C(/C1=CC=CC=C1)C2=CC=C(OCCN(C)C)C=C2)C3=CC=CC=C3

InChI

InChIKey=FQZYTYWMLGAPFJ-OQKDUQJOSA-N

InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-;

HIDE SMILES / InChI

Molecular Formula	C6H8O7
Molecular Weight	192.1235
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C26H29NO
Molecular Weight	371.5146
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00675 | https://www.ncbi.nlm.nih.gov/pubmed/18316672 | https://www.ncbi.nlm.nih.gov/pubmed/2021551 | https://www.drugs.com/tamoxifen.html | http://reference.medscape.com/drug/soltamox-tamoxifen-342183

Tamoxifen (brand name Nolvadex), is selective estrogen receptor modulators (SERM) with tissue-specific activities for the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen itself is a prodrug, having relatively little affinity for its target protein, the estrogen receptor (ER). It is metabolized in the liver by the cytochrome P450 isoform CYP2D6 and CYP3A4 into active metabolites such as 4-hydroxytamoxifen (4-OHT) (afimoxifene) and N-desmethyl-4-hydroxytamoxifen (endoxifen) which have 30–100 times more affinity with the ER than tamoxifen itself. These active metabolites compete with estrogen in the body for binding to the ER. In breast tissue, 4-OHT acts as an ER antagonist so that transcription of estrogen-responsive genes is inhibited. Tamoxifen has 7% and 6% of the affinity of estradiol for the ERα and ERβ, respectively, whereas 4-OHT has 178% and 338% of the affinity of estradiol for the ERα and ERβ. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects. Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor (ER)-positive (ER+) breast cancer in pre- and post-menopausal women. Additionally, it is the most common hormone treatment for male breast cancer. Patients with variant forms of the gene CYP2D6 (also called simply 2D6) may not receive full benefit from tamoxifen because of too slow metabolism of the tamoxifen prodrug into its active metabolites. Tamoxifen is used as a research tool to trigger tissue-specific gene expression in many conditional expression constructs in genetically modified animals including a version of the Cre-Lox recombination technique. Tamoxifen has been shown to be effective in the treatment of mania in patients with bipolar disorder by blocking protein kinase C (PKC), an enzyme that regulates neuron activity in the brain. Researchers believe PKC is over-active during the mania in bipolar patients.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Estrogen receptor alpha 134 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23786452	Antagonist 2849	39.0 nM [IC50]
Estrogen receptor beta 113 Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22647217	Antagonist 2849	1660.0 nM [IC50]
Estrogen receptor 72 Target ID: CHEMBL2093866 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15658851	Antagonist 2849	580.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 432 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf	Primary	Approved 8583	NOLVADEX Approved Use Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS) In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5 year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or •At least 2 first degree relatives with a history of breast cancer, and a personal history of at least 1 breast biopsy; or •LCIS Age 40 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or •At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or •One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer; or •History of 1 breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: •Five-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-888-838-2872. There are insufficient data available regarding the effect of tamoxifen on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. In the NSABP P-1 trial, tamoxifen treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (see Table 3 in CLINICAL PHARMACOLOGY ). Launch Date 1977
Reduction in breast cancer incidence 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf	Preventing	Approved 8583	NOLVADEX Approved Use Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS) In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5 year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or •At least 2 first degree relatives with a history of breast cancer, and a personal history of at least 1 breast biopsy; or •LCIS Age 40 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or •At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or •One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer; or •History of 1 breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: •Five-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-888-838-2872. There are insufficient data available regarding the effect of tamoxifen on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. In the NSABP P-1 trial, tamoxifen treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (see Table 3 in CLINICAL PHARMACOLOGY ). Launch Date 1977
Ductal carcinoma in situ 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf	Primary	Approved 8583	NOLVADEX Approved Use Metastatic Breast Cancer Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. Adjuvant Treatment of Breast Cancer Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. Tamoxifen reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen therapy for breast cancer. Ductal Carcinoma in Situ (DCIS) In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support 5 years of adjuvant tamoxifen therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5 year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5 year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or •At least 2 first degree relatives with a history of breast cancer, and a personal history of at least 1 breast biopsy; or •LCIS Age 40 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or •At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or •One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: •At least 2 first degree relatives with a history of breast cancer; or •History of 1 breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: •One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or •History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: •Five-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-888-838-2872. There are insufficient data available regarding the effect of tamoxifen on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. In the NSABP P-1 trial, tamoxifen treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (see Table 3 in CLINICAL PHARMACOLOGY ). Launch Date 1977

C_max

Value	Dose	Co-administered	Analyte	Population
187 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TAMOXIFEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE food status: UNKNOWN
63.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8740091	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		TAMOXIFEN blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4110 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf	20 mg 1 times / day steady-state, oral dose: 20 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TAMOXIFEN plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE food status: UNKNOWN
3370.1 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8740091	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		TAMOXIFEN blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
209.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8740091	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:		TAMOXIFEN blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
240 mg 3 times / day multiple, oral MTD Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1358168/	unhealthy, Median age 50 years Health Status: unhealthy Age Group: Median age 50 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1358168/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (grade 1-4) Vomiting (grade 1-4) Dizziness (grade 1-4) Unsteadiness (grade 1-4) Malaise (grade 1-4) Sources: https://pubmed.ncbi.nlm.nih.gov/1358168/
240 mg 1 times / day multiple, oral MTD Dose: 240 mg, 1 times / day Route: oral Route: multiple Dose: 240 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/	unhealthy, Median age 53 years Health Status: unhealthy Age Group: Median age 53 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/	Other AEs: Neutropenia, Thrombocytopenia... Other AEs: Neutropenia (grade 4, 10%) Thrombocytopenia (grade 2, 10%) Hemoglobin decreased Serum creatinine increased Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/
280 mg 1 times / day multiple, oral Studied dose Dose: 280 mg, 1 times / day Route: oral Route: multiple Dose: 280 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/	unhealthy, Median age 53 years Health Status: unhealthy Age Group: Median age 53 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/	DLT: Neutropenia, Thrombocytopenia... Disc. AE: Nausea, Vomiting... Other AEs: Serum creatinine increased... Dose limiting toxicities: Neutropenia (grade 4, 22.2%) Thrombocytopenia (grade 4, 22.2%) AEs leading to discontinuation/dose reduction: Nausea (11.1%) Vomiting (11.1%) Anorexia (11.1%) Septicemia (11.1%) Other AEs: Serum creatinine increased (11.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/9041168/
30 mg 2 times / day multiple, oral Studied dose Dose: 30 mg, 2 times / day Route: oral Route: multiple Dose: 30 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/	unhealthy, Median age 61 years Health Status: unhealthy Age Group: Median age 61 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (grade 3, 1.3%) Vomiting (grade 3, 1.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/
60 mg 2 times / day multiple, oral Studied dose Dose: 60 mg, 2 times / day Route: oral Route: multiple Dose: 60 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/	unhealthy, Median age 61 years Health Status: unhealthy Age Group: Median age 61 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/	Other AEs: Nausea, Vomiting... Other AEs: Nausea (grade 3, 0.8%) Vomiting (grade 3, 0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/12395333/
10 mg 2 times / day multiple, oral Recommended Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/017970Orig1s052.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/017970Orig1s052.pdf	Other AEs: Uterine neoplasms malignant NEC, Stroke... Other AEs: Uterine neoplasms malignant NEC Stroke Pulmonary embolism Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/017970Orig1s052.pdf
700 mg 1 times / day multiple, oral Highest studied dose Dose: 700 mg, 1 times / day Route: oral Route: multiple Dose: 700 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7564501/	unhealthy, median age 50 years Health Status: unhealthy Age Group: median age 50 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7564501/	Sources: https://pubmed.ncbi.nlm.nih.gov/7564501/
100 mg/m2 2 times / day multiple, oral MTD Dose: 100 mg/m2, 2 times / day Route: oral Route: multiple Dose: 100 mg/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	unhealthy, median age 51 years Health Status: unhealthy Age Group: median age 51 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	Other AEs: Mental status changes... Other AEs: Mental status changes (grade 3, 33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/
125 mg/m2 2 times / day multiple, oral Studied dose Dose: 125 mg/m2, 2 times / day Route: oral Route: multiple Dose: 125 mg/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	unhealthy, median age 51 years Health Status: unhealthy Age Group: median age 51 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	DLT: Thrombocytopenia... Other AEs: QT interval prolonged, Thrombosis venous deep... Dose limiting toxicities: Thrombocytopenia (grade 4, 16.7%) Other AEs: QT interval prolonged (16.7%) Thrombosis venous deep (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/
75 mg/m2 2 times / day multiple, oral Studied dose Dose: 75 mg/m2, 2 times / day Route: oral Route: multiple Dose: 75 mg/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	unhealthy, median age 51 years Health Status: unhealthy Age Group: median age 51 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/	Other AEs: Thrombosis venous deep... Other AEs: Thrombosis venous deep (grade 3, 25%) Sources: https://pubmed.ncbi.nlm.nih.gov/21353747/
680 mg/m2 1 times / day single, oral Highest studied dose Dose: 680 mg/m2, 1 times / day Route: oral Route: single Dose: 680 mg/m2, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/	unhealthy, median age 58 years Health Status: unhealthy Age Group: median age 58 years Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/	Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/
230 mg/m2 2 times / day multiple, oral Studied dose Dose: 230 mg/m2, 2 times / day Route: oral Route: multiple Dose: 230 mg/m2, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/	unhealthy, median age 58 years Health Status: unhealthy Age Group: median age 58 years Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/	DLT: Grand mal seizure... Dose limiting toxicities: Grand mal seizure (33.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/1359155/
250 mg/m2 multiple, oral Studied dose Dose: 250 mg/m2 Route: oral Route: multiple Dose: 250 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf	Other AEs: QT interval prolonged... Other AEs: QT interval prolonged Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf
400 mg/m2 multiple, oral Studied dose Dose: 400 mg/m2 Route: oral Route: multiple Dose: 400 mg/m2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lbl.pdf	Other AEs: Tremor, Hyperreflexia... Other AEs: Tremor Hyperreflexia Unsteady gait Dizziness Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	substrate 1193 inhibitor 2438 inducer 440	substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741 CYP1A2 2153 CYP2B6 926 CYP2C8 1057 CYP2C19 2057	CYP1A1 389 CYP1A2 1197 CYP3A 220 CYP2C19 1119 CYP2B6 776 P-gp 2052 SULT1A1 37 UGT2B7 456 UGT1A4 399 UGT1A3 470 UGT1A1 479 UGT1A8 323 UGT1A9 423 UGT2B17 237 CYP3A5 446 CYP2C8 810	CYP1A2 832 CYP2B6 669 CYP2C8 198 CYP2C19 329

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP1A2 2333	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	no
CYP3A4 2633	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.178 uM]	norendoxifen 4
CYP2B6 1160	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.187 uM]	norendoxifen 4
CYP2C19 2141	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.3 uM]	norendoxifen 4
CYP2C8 1117	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.4 uM]	norendoxifen 4
CYP2C9 2497	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.488 uM]	norendoxifen 4
CYP1A2 2333	inducer 1966 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [EC50 0.518 uM]	norendoxifen 4
CYP2C9 2497	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [IC50 0.21 uM]	norendoxifen 4
CYP2C19 2141	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [IC50 0.32 uM]	norendoxifen 4
CYP2C8 1117	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=10 Page: -	yes [IC50 2.4 uM]	norendoxifen 4
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	no
CYP1A1 389	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
CYP1A2 1197	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
CYP2B6 776	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes
CYP2C8 810	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes
CYP3A 220	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
CYP3A5 446	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
SULT1A1 37	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf#page=20 Page: -	yes
UGT1A1 479	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
UGT1A3 470	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
UGT1A4 399	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf#page=20 Page: -	yes
UGT1A8 323	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
UGT1A9 423	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
UGT2B17 237	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866846/pdf/204_2017_Article_2147.pdf#page=7 Page: -	yes
UGT2B7 456	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021807s005lbl.pdf#page=20 Page: -	yes
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0	yes	unknown (co-administration study) Comment: Although concomitant administration of CYP2D6 inhibitors reduces the plasma concentration of endoxifen, a potent metabolite, the clinical significance is not well established [see Drug Interactions (7.4)]. The mean steady-state endoxifen plasma concentration in patients taking CYP2D6 inhibitors was significantly reduced compared to those not taking concomitant CYP2D6 inhibitors (14.8 ± 10.6 versus 26.7 ± 15.4 ng/mL). The mean steady-state plasma concentration of endoxifen in CYP2D6 normal metabolizers who were not receiving CYP2D6 inhibitors was 31.4 ± 14.7 ng/mL compared to 8.8 ± 3.5 ng/mL in CYP2D6 normal metabolizers receiving potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) with tamoxifen. The plasma levels of endoxifen in CYP2D6 normal metabolizers taking potent CYP2D6 inhibitors were similar to the levels observed in CYP2D6 poor metabolizers taking no CYP2D6 inhibitors (8.8 versus 7.2 ng/mL). Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021807s000_MedR_ClinPharmR.pdf#page=15 Page: 15.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/25680947/ Page: -

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:41774	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:41774
ChemicalBook	CB9438781	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9438781
eMolecules	594967	https://www.emolecules.com/cgi-bin/more?vid=594967
ZINC	ZINC000001530689	http://zinc15.docking.org/substances/ZINC000001530689

PubMed

Title	Date	PubMed
Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women.	2003-06-13	12801273
Comparison of the reporter gene assay for ER-alpha antagonists with the immature rat uterotrophic assay of 10 chemicals.	2003-04-30	12765246
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.	2003-04	12739759
Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand.	2003-04	12721755
Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities.	2003-04	12676605
Tamoxifen and gallstone formation in postmenopausal breast cancer patients: retrospective cohort study.	2003-04	12658480
The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen.	2003-03-11	12627041
Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells.	2003-02	12710998
Cell proliferation, apoptosis, and expression of cyclin D1 and cyclin E as potential biomarkers in tamoxifen-treated mammary tumors.	2003-02	12602925
Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs.	2003-02	12586603
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.	2003-01	12492585
Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.	2003-01	12490491
Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.	2003	12661780
Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.	2002-12-07	12469151
[How I manage patients developing thromboembolic complications as a result of breast cancer treatment with tamoxifen ].	2002-12	12632830
Increases in mouse uterine heat shock protein levels are a sensitive and specific response to uterotrophic agents.	2002-12	12460799
Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model.	2002-10-09	12365480
Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.	2002-10	12419016
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.	2002-10	12393984
In vitro antiestrogenic effects of aryl methyl sulfone metabolites of polychlorinated biphenyls and 2,2-bis(4-chlorophenyl)-1,1-dichloroethene on 17beta-estradiol-induced gene expression in several bioassay systems.	2002-10	12377985
The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.	2002-10	12372848
Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto- and xenoestrogens.	2002-10	12370124
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.	2002-09-14	12243915
Molecular identification of P-glycoprotein: a role in lens circulation?	2002-09	12202523
A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.	2002-08-15	12174927
Size and oxidative susceptibility of low-density lipoprotein particles in breast cancer patients with tamoxifen-induced fatty liver.	2002-08	12161495
Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids.	2002-07	12224631
Functional analysis of the rat bile salt export pump gene promoter.	2002-07	12135489
Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy.	2002-05-20	12085202
Tamoxifen enhancement of TNF-alpha induced MnSOD expression: modulation of NF-kappaB dimerization.	2002-05-16	12032862
Estrogen receptor binding assay of chemicals with a surface plasmon resonance biosensor.	2002-05	12127041
Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.	2002-05	12058881
Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.	2002-05	12058236
Aromatase-deficient (ArKO) mice are retrieved from severe hepatic steatosis by peroxisome proliferator administration.	2002-04	11929713
Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation.	2002-03-26	11911415
Tamoxifen-induced cirrhotic process.	2002-02-15	11843860
Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.	2002-02-10	11803101
[A case of locally recurrent breast cancer in which phlebothrombosis of the right leg after hormonal therapy using a high dose of toremifene citrate].	2002-01	11816466
High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes.	2002	12523579
Tamoxifen-related porphyria cutanea tarda.	2002	12180481
Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.	2001-12-01	11731420
Relationship between expression of sex steroid receptors and structure of the seminal vesicles after neonatal treatment of rats with potent or weak estrogens.	2001-12	11748029
First do no harm: extending the debate on the provision of preventive tamoxifen.	2001-11-02	11720461
Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors.	2001-11-02	11711029
[132 grams of tamoxifen: ultrasonographic and MRI appearance of endometrial carcinoma].	2001-11	11894549
A case with cerebral thrombosis receiving tamoxifen treatment.	2001-11	11784361
Bisphenol A enhances cadmium toxicity through estrogen receptor.	2001-09	11771854
Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.	2001-08	11570696
Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.	2001-07	11759963
Pure antiestrogens and breast cancer.	2001	11922402

Patents

Sample Use Guides

In Vivo Use Guide

For patients with breast cancer, the recommended daily dose is 20-40 mg. Dosages greater than 20 mg per day should be given in divided doses (morning and evening).

Route of Administration: Oral

In Vitro Use Guide

HELNalpha and HELNbeta two human cervix adenocarcinoma cell lines derived from HeLa cells stably transfected with the reporter gene ERE-betaGlob-Luc-SVNeo and the expression plasmids ERalpha or ERbeta respectively, were used to quantify the antiestrogenic and estrogenic effects of Tamoxifen. These cells were routinely cultivated in DMEM phenol red free, supplemented with 5% sFBS, 2 mM glutamine, 1% penicillin/streptomycin, 1 mg/mL Geneticin, and 0.5 mkg/mL puromycin to ensure appropriate antibiotic selection. For the assay, cells were trypsinized from the maintenance flask with phenol red free trypsin (0.05%)-EDTA (0.02%) (HyClone, Logan, UT) and seeded in an opaque 96-well plate (Nunc) at a density of 7.5 x 10^4 cells/well in a final volume of 100 mkL of assay medium (DMEM, phenol red free, supplemented with 3% sFBS, 2 mM glutamine, and penicillin/streptomycin). Five hours later, cells were adherent. Serial dilutions of Tamoxifen or DMSO as diluent control were then added in the presence of a fixed concentration of 17beta-estradiol (10^-10 M in HELNalpha and 10^-9 M in HELNbeta) to triplicate microcultures. Faslodex (Tocris, 10^-8 M) was used as a baseline indicator. Cells were incubated for 20 h at 37 °C in a 5% CO2 humidified incubator before being processed for luciferase determination. Medium was aspirated and 100 mkL of a 1:1 mixture of LucLite (Perkin-Elmer, Life Science, Boston, MA)/assay medium was added to each well. Plates were then sealed with a Topseal and left in the dark for 10 min before luminescence activity was determined by counting the plates for 6 s in a beta-TopCount (Packard Instrument Company, Meriden, CT).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:53 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:53 GMT 2025`
Record UNII	7FRV7310N6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KESSAR

Preferred Name

English

TAMOXIFEN CITRATE

Official Name

English

NOLVADEX

Brand Name

English

NOURYTAM

Common Name

English

TAMOFENE

Brand Name

English

SOLTAMOX

Brand Name

English

ETHANAMINE, 2-(4-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYL, (Z)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)

Common Name

English

TAMOXIFEN CITRATE [MI]

Common Name

English

TAMOXIFEN CITRATE [WHO-IP]

Common Name

English

TAMOXIFEN CITRATE [USAN]

Common Name

English

TAMOXIFEN CITRATE [ORANGE BOOK]

Common Name

English

TAMOXIFEN CITRATE [MART.]

Common Name

English

TOMAXASTA

Common Name

English

ICI-46474

Code

English

TAMOXIFEN CITRATE [VANDF]

Common Name

English

ZITAZONIUM

Brand Name

English

I.C.I.46474 CITRATE

Code

English

NSC-180973

Code

English

NSC-757345

Code

English

TAMOXIFEN CITRATE [EP MONOGRAPH]

Common Name

English

ICI 46,474

Code

English

TAMOXIFEN CITRATE [USP-RS]

Common Name

English

TAMOXIFEN CITRATE [USP MONOGRAPH]

Common Name

English

TAMOXIFEN CITRATE [JAN]

Common Name

English

ZEMIDE

Brand Name

English

(Z)-2-(P-(1,2-DIPHENYL-1-BUTENYL)PHENOXY)-N,N-DIMETHYLETHYLAMINE CITRATE (1:1)

Common Name

English

TAMOXIFENI CITRAS [WHO-IP LATIN]

Common Name

English

Tamoxifen citrate [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1821